Подборка литературы по раку простаты

Подборка литературы, посвященной скринингу рака простаты и ассоциированным с ним биомаркерам:

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49

2. Home page of Prostate Cancer Foundation. Prostate Cancer Foundation.http://www.prostatecancerfoundation.org

3. Stanford JL, Stephenson RA, Coyle LM. et al. Prostate Cancer Trends 1973-1995, NIH Pub No 99-4543. Bethesda, MD: SEER Program, National Cancer Institute. 1999

4. Prostate Cancer Screening: A Decision Guide for African Americans. US Department of Health and Human Services, Centers for Disease Control and Prevention (CDC).http://www.ustoo.org/PDFs/CDC_PCa_Screen_Guide_AA.pdf

5. Atkinson AJJr, Colburn WA, DeGruttola VG, DeMets DL. et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Biomarkers Definitions Working Group. Clinical Pharmacol & Therapeutics. 2001;69:89-95

6. A Framework for Biomarker and Surrogate Endpoint Use in Drug Development. Woodcock J.http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4079S2_03_Woodcock.ppt

7. Dictionary of Cancer Terms. National Cancer Institute. http://www.cancer.gov/dictionary/?searchTxt=biomarker

8. Rolan P. The contribution of clinical pharmacology surrogates and models to drug development: a critical appraisal. Br J Clin Pharmacol. 1997;44:219-25

9. Ciarmiello A, Del Vecchio S, Silvestro P. et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 1998;16:1677-83

10. Committee on Developing Biomarker-Based Tools for Cancer Screening Diagnosis and Treatment. Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment. Washington DC: National Academies Press. 2007

11. Lagakos SW, Hoth DF. Surrogate markers in AIDS: where are we? Where are we going?. Ann Intern Med. 1992;116:599-601

12. Sawyers CL. The cancer biomarker problem. Nature. 2008;452:548-52

13. Ross RK, Pike MC, Coetzee GA. et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 1998;58:4497-504

14. Smith RA, Mettlin CJ, Eyre H. Cancer Medicine: Cancer Screening and Early Detection. In: (ed.) Kufe DW. et al. Cancer Medicine. Hamilton, Canada: BC Decker Inc. 2003

15. Prostate Cancer - Biology, Diagnosis, Pathology, Staging, and Natural History. Theodorescu D, Krupski T.http://www.emedicine.com

16. Bostwick DG. The pathology of early prostate cancer. CA Cancer J Clin. 1989;39:376-93

17. Stamey TA, Freiha FS, McNeal JE. et al. Localized prostate cancer treatment: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71:933-8

18. Epstein JI, Walsh PC, Carmichael M. et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-74

19. Ohori M, Wheeler TM, Dunn JK. et al. The pathologic features and prognosis of prostate cancers detectable with current diagnostic tests. J Urol. 1994;152:1714-20

20. Montie JM, Wood DP, Pontes JE. et al. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer. 1989;63:381-5

21. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol.1994;152:1732-6

22. Oh WK, Hurwitz M, D'Amico AV. et al. Neoplasms of the Prostate. In: (ed.) Kufe DW. et al. Cancer Medicine. Hamilton, Canada: BC Decker Inc. 2003

23. Yano M, Imamoto T, Suzuki H. et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol. 2007;51:375-80

24. Fielding LP, Genglio-Presier CM, Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer. 1992;70:2367-77

25. Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am. 1975;2:105-24

26. American Joint Committee on Cancer. Prostrate: in AJCC Cancer Staging Manual, 6^th ed. New York, NY: Springer. 2002:309-16

27. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Semin Surg Oncol. 1994;10:60-72

28. American Joint Committee on Cancer. Prostate cancer. In: (ed.) Fleming ID, Cooper JS, Henson DE, Hutter RVP. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott. 1997:219-24

29. Montie JE. Staging of prostate cancer: current TNM classification and future prospects for prognostic factors. Cancer.1995;75(7 Suppl):1814-8

30. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: The Johns Hopkins experience with tumours found on transurethral resection (stages T1A and T1B) and on needle biopsy. J Urol. 1994;152:1721-9

31. Mettlin C, Lee F, Drago J. et al. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer. 1991;67:2949-58

32. Catalona WJ, Smith DS, Ratliff TL. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-61

33. Basler JW, Thompson IM. Lest we abandon digital rectal examination as a screening test for prostate cancer. J NCI.1998;90:1761-3

34. Mahon SM. Screening for prostate cancer: informing men about their options. Clinical Journal of Oncology Nursing. 2005;9:5

35. Yedema CA, Kenemans P, Voorhorst F. et al. CA 125 half-life in ovarian cancer. A multivariate survival analysis. Br J Cancer. 1993;67:1361-7

36. Jacobsen SJ, Bergstralh EJ, Katusic SK. et al. Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology. 1998;52:173-9

37. Friedman GD, Hiatt Ram, Quesenberry CP. et al. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet. 1991;337:1526-9

38. Richert-Boe KE, Humphrey LL, Glass AG. et al. Screening digital rectal examination and prostate cancer mortality: a case-control study. J Med Screen. 1998;5:99-103

39. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force.Ann Intern Med. 2002;137:917-29

40. Hara M, Koyanagi Y, Inoue T. et al. Some physico-chemical characteristics of “-seminoprotein”, an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII. Nihon Hoigaku Zasshi.1971;25:322-4

41. Li TS, Beling CG. Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril.1973;24:134-44

42. Sensabaugh GF, Golden VL. Phenotype dependence in the inhibition of red cell acid phosphatase (ACP) by folates. Am J Hum Genet. 1978;30:553-60

43. Wang MC, Valenzuela LA, Murphy GP. et al. Purification of a human prostate specific antigen. Invest Urol. 1979;17:159-63

44. Stamey TA, Yang N, Hay AR. et al. E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-16

45. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen. J Urol. 1994;152:1358-68

46. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen. A decade of discovery—what we have learned and where we are going. J Urol. 1999;162:293-306

47. Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008;101:5-10

48. Chu MT. Prostate-specific antigen and early detection of prostate cancer. Tumor Biol. 1997;18:123-34

49. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am. 1997;24:275-82

50. Stenman UH, Leinonen J, Zhang WM. Standardization of PSA determinations. Scand J Clin Lab Invest (Suppl). 1995;221:45-51

51. Carter HB, Pearson JD, Metter EJ. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-20

52. Moul JW, Sesterhenn IA, Connelly RR. et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA. 1995;274:1277-81

53. Presti JCJr, Hovey R, Bhargava V. et al. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate: ethnic variations. J Urol. 1997;157:907-11

54. Morgan TO, Jacobsen SJ, McCarthy WF. et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med. 1996;335:304-10

55. Partin AW, Yoo J, Carter HB. et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-4

56. Partin AW, Carter HB, Chan DW. et al. Prostate specific antigen in the staging of localized prostate cancer. Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990;143:747-52

57. Stamey TA, Dietrick DD, Issa MM. Large, organ confined, impalpable transition zone prostate cancer. Association with metastatic levels of prostate specific antigen. J Urol. 1993;149:510-5

58. Catalona WJ, Smith DS, Ratliff TL. et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-54

59. Balducci L, Pow-Sang J, Friedland J. et al. Prostate cancer. Clin Geriatr Med. 1997;13:283-306

60. SEER Cancer Statistics Review, 1975-2005. Ries LA, Melbert D, Krapcho M, et al. http://seer.cancer.gov/csr/1975_2005/

61. Hankey BF, Feuer EJ, Clegg LX. et al. Cancer surveillance series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017

62. Feuer EJ, Etzioni R, Cronin KA. et al. A. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res. 2004;13:421

63. Polednak AP. Estimating the prevalence of cancer in the United States. Cancer. 1997;80:136-41

64. Kirby R, Kirby M, Fitzpatrick J. et al. Shared Care for Prostate Disease. Oxford: ISIS Medical Media. 1994

65. Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annual Review of Public Health. 2001;22:91-113

66. Hakama M, Auvinen A. Cancer screening. In: (ed.) Heggenhougen Kl, Quah SR. International Encyclopedia of Public Health. San Diego, CA: Academic Press. 2008:464-80

67. Andriole GL, Grubb RL III, Buys SS. et al. The PLCO Project Team. Mortality results from a randomized Ppostate-cancer screening trial. NEJM. 2009;360:1310-9

68. Aus G, Ahlgren G, Bergdahl S. et al. Infection after transrectal core biopsies of the prostate--risk factors and antibiotic prophylaxis. Br J Urol. 1996;77:851-5

69. Rietbergen JB, Kruger AE, Kranse R. et al. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology.1997;49:875-80

70. Yao SL, Lu-Yao G. Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. J NCI. 1999;91:1950-6

71. Alibhai SMH, Leach M, Tomlinson G. et al. 30-Day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J NCI. 2005;97:1525-32

72. Potosky AL, Davis WW, Hoffman RM. et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J NCI. 2004;96:1358-67

73. Lim AJ, Brandon AH, Fiedler J. et al. Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol. 1995;154:1420-5

74. Hamilton AS, Stanford JL, Gilliland FD. et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19:2517-26

75. Fowler FJ Jr, McNaughton Collins M; Walker Corkery E. et al. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer. 2002;95:287-95

76. Tsai HK, D'Amico AV, Sadetsky N. et al. Chen, MH; Carroll, PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. JNCI. 2007;99:1516-24

77. Punnen S, Nam RK. Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: A clinical conundrum in the PSA era. Surg Oncol. 2009;18:192-9

78. Cooner WH, Mosley BR, Rutherford CL Jr. et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990;143:1146-52

79. Brawer MK, Chetner MP, Beatie J. et al. Screening for prostatic carcinoma with prostate carcinoma with prostate specific antigen. J Urol. 1992;147:841-5

80. Labrie F, Dupont A, Suburu R. et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol.1992;147:846-51

81. Catalona WJ, Richie JP, Ahmann FR, et al.Comparison of digital rectal examination, serum prostate specific antigen in the early detection of prostate cancer. Results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-90

82. Greenlee RT, Murray T, Bolden S. et al. Cancer statistics 2000. CA Cancer J Clin. 2000;50:7-33

83. Potosky AL, Miller BA, Albertsen PC. et al. The role of increasing detection in the rising incidence of prostate cancer.JAMA. 1995;273:548-52

84. Moul JW. Treatment options for prostate cancer. Part I. Staged, grade, PSA, and changes in the 1990's. Am J Managed Care. 1998;4:1031-6

85. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11:167-70

86. Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer. 1997;80:1835-44

87. Mettlin CJ, Murphy GP, Rosenthal DS. et al. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society.Cancer. 1998;83:1679-84

88. Tarone RE, Chu KC, Brawley OW. Implications of stage specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11:167-70

89. Smart CR. The results of prostate carcinoma screening in the US as reflected in the Surveillance, Epidemiology, and End Results program. Cancer. 1997;80:1835-44

90. Mettlin CJ, Murphy GP, Rosenthal DS. et al. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the US. The American College of Surgeons Commission on Cancer and the American Cancer Society.Cancer. 1998;83:1679-84

91. Bunting PS. A guide to the interpretation of serum prostate specific antigen levels. Clin Biochem. 1995;28:221-41

92. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer— part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J NCI. 1999;91:1025-32

93. Bettencourt MC, Bauer JJ, Sesterhenn IA. et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 1996;156:1064-8

94. Stephenson RA. Population-based prostate cancer trends in the PSA era: data from the Surveillance, Epidemiology, and End Results Program. Monographs in Urology. 1998:3-19

95. Etzioni R, Legler JM, Feuer EJ. et al. Cancer surveillance series: interpreting trends in prostate cancer— part III: quantifying the link between population prostate specific antigen testing and recent declines in prostate cancer mortality. J NCI. 1999;91:1033-9

96. Coley CM, Barry MJ, Fleming C. et al. Early detection of prostate cancer. Part 1. Prior probability and effectiveness of tests.Ann Intern Med. 1997;126(5):394-406

97. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res. 2004;10:3943-53

98. Hartwell L, Mankoff D, Paulovich A. et al. Cancer biomarkers: a systems approach. Nature Biotechnology. 2006;24:905-8

99. Cox TM. Biomarkers in lysosomal storage diseases. Fabry disease: Perspectives from 5 years of FOS. Mehta, A; Beck, M; Sunder-Plassmann, G, editors. Oxford (UK): Oxford PharmaGenesis Ltd. 2006

100. A Framework for Biomarker and Surrogate Endpoint Use in Drug Development. Woodcock J.http://www.fda.gov/ohrms/dockets/ac/04/

101. Deegan PB, Moran MT, McFarlane I. et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis. 2005;35:259-67

102. Pepe MS, Etzioni R, Feng Z. et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst.2001;93:1054-61

103. Barker PE. Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST). Ann NY Acad Sci. 2003;983:142-50

104. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nature Reviews Cancer.2005;5:845-56

105. Nadler RB, Humphrey PA, Smith DS. et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154:407-13

106. Makarov DV, Loeb S, Getzenberg RH. et al. Biomarkers for prostate cancer. Ann Rev Medicine. 2009;60:139-51

107. Taskén KA, Angelsen A, Svindland A. et al. Markers for diagnosis, prediction and prognosis of prostate cancer. Tidsskr Nor Laegeforen. 2005;125:3279-82

108. Gutman AB, Gutman EB. An “acid” phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest. 1938;17:473-8

109. Veeramani S, Yuan TC, Chen SJ. et al. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer. 2005;12:805-22

110. Gutman AB, Gutman EB, Robinson JN. Determination of serum 'acid' phosphatase activity in differentiating skeletal metastases secondary to prostatic carcinoma from Paget's disease of bone. Am J Cancer. 1940;38:103-8

111. Doe RP, Seal US. Acid phosphatase in urology. Surg Clin North Am. 1965;45:1455-66

112. Whitesel JA, Donohue RE, Mani JH. et al. Acid phosphatase: its influence on the management of carcinoma of the prostate. J Urol. 1984;131:70-7

113. Johnson DE, Prout GR, Scott WW. et al. Clinical significance of serum acid phosphatase levels inadvanced prostatic carcinoma. Urology. 1976;8:123-6

114. Bishop MC, Hardy JG, Taylor MC. et al. Bone imaging and serum phosphatases in prostatic carcinoma. Br J Urol.1985;57:317-24

115. Lilja H, Haese A, Björk T. et al. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol. 1999;162:2029-34

116. Sokoll LJ, Partin AW, Mikolajczyk SD. et al. ProPSA in relation to free PSA gives the best performance in detecting cancer in the 2.5-4.0 ng/mL total PSA range. J Urol. 2002;167:286

117. Ercole CJ, Lange PH, Mathisen M. et al. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol. 1987;138:1181-4

118. Pound CR, Partin AW, Eisenberger MA. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-7

119. Lowe FC, Trauzzi SJ. Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol Clin North Am. 1993;20:589-95

120. Han M, Piantadosi S, Zahurak ML. et al. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology. 2001;57:707-11

121. Oberaigner W, Horninger W. Klocker H. Schönitzer D; Stühlinger, W; Bartsch, G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol. 2006;164:376-84

122. Antenor JA, Roehl KA, Eggener SE. et al. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology. 2005;66:156-60

123. Nadler RB, Loeb S, Roehl KA. et al. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol. 2005;174:2154-7

124. Thompson IM, Pauler DK, Goodman PJ. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004;350:2239-46

125. Han M, Partin AW, Chan DY. et al. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol. 2004;171:23-36

126. Han M, Partin AW, Pound CR. et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001;28:555-65

127. Freedland SJ, Humphreys EB, Mangold LA. et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-9

128. Kuefer R, Varambally S, Zhou M. et al. Alpha-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol. 2002;161:841-8

129. Zha S, Ferdinandusse S, Denis S. et al. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res. 2003;63:7365-76

130. Jiang Z, Wu CL, Woda BA. et al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker. Histopathology. 2004;45:218-25

131. Rubin MA, Zhou M, Dhanasekaran SM. et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002;287:1662-70

132. Jiang Z, Wu CL, Woda BA. et al. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol. 2002;26:1169-74

133. Luo J, Zha S, Gage WR. et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res.2002;62:2220-6

134. Rogers CG, Ya G, Zha S. et al. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme A racemase protein. J Urol. 2004;172:1501-3

135. Sreekumar A, Laxman B, Rhodes DR. et al. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J NCI. 2004;96:834-43

136. Cardillo MR, Gentile V, Ceccariello A. et al. Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer?. BMC Cancer. 2005;5:111

137. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30:445-600

138. Lee WH, Morton RA, Epstein JI. et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA. 1994;91:11733-7

139. Harden SV, Guo Z, Epstein JI. et al. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol. 2003;169:1138-42

140. Jerónimo C, Varzim G, Henrique R. et al. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2002;11:445-50

141. Jeronimo C, Usadel H, Henrique R. et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J NCI. 2001;93:1747-52

142. Chu DC, Chuang CK, Fu JB. et al. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma. J Urol. 2002;167:1854-8

143. Brooks JD, Weinstein M, Lin X. et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomark Prev. 1998;7:531-6

144. Cairns P, Esteller M, Herman JG. et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res. 2001;7:2727-30

145. Lin X, Tascilar M, Lee WH. et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol. 2001;159:1815-26

146. Bastian PJ, Ellinger J, Schmidt D. et al. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?. Eur J Med Res. 2004;9:523-7

147. Gonzalgo ML, Pavlovich CP, Lee SM. et al. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res. 2003;9:2673-7

148. Gonzalgo ML, Nakayama M, Lee SM. et al. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology. 2004;63:414-8

149. Simon JP, Aunis D. Biochemistry of the chromogranin A protein family. Biochem J. 1989;262:1-13

150. Helman LJ, Ahn TG, Levine MA. et al. Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA. J Biol Chem. 1988;263:11559-63

151. Berruti A, Mosca A, Tucci M. et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer. 2005;12:109-17

152. Deftos LJ. Granin-A, parathyroid hormone-related protein, and calcitonin gene products in neuroendocrine prostate cancer. Prostate (Suppl). 1998;8:23-31

153. Berruti A, Dogliotti L, Mosca A. et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer.2000;88:2590-7

154. Zaky Ahel M, Kovacic K, Kraljic I. et al. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. Anticancer Res. 2001;21:1475-9

155. Ferrero-Pous M, Hersant AM, Pecking A. et al. Serum chromogranin-A in advanced prostate cancer. BJU Int. 2001;88:790-6

156. Cabrespine A, Guy L, Gachon F. et al. Circulating chromogranin A and hormone refractory prostate cancer chemotherapy.J Urol. 2006;175:1347-52

157. Sasaki T, Komiya A, Suzuki H. et al. Changes in chromogranin A serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol. 2005;48:224-30

158. Zitella A, Berruti A, Destefanis P. et al. Gruppo Oncologico Urologico Piemontese (GOUP). Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia. Clin Chim Acta. 2007;377:103-7

159. Ramírez ML, Nelson EC, Evans CP. Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer Prostatic Diseases. 2008;11:216-29

160. Isshiki S, Akakura K, Komiya A. et al. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol. 2002;167:512-5

161. Cheville JC, Tindall D, Boelter C. et al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer. 2002;95:1028-36

162. Fracalanza S, Prayer-Galetti T, Pinto F. et al. Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination. Urol Int. 2005;75:57-61

163. Deftos LJ, Abrahamsson PA. Granins and prostate cancer. Urology. 1998;51:141-5

164. Riegman PH, Vlietstra RJ, Klaassen P. et al. The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett. 1989;247:123-6

165. Dawson NA, Vogelzang NJ. Prostate Cancer. New York: Wiley-Liss Inc. 1994

166. Myrtle JF, Klimley PG, Ivor LP. et al. Clinical utility of prostate specific antigen (PSA) in the management of prostate cancer. Advances in cancer diagnostics. San Diego, CA: Hybritech Inc. 1986:1-4

167. Xiao Z, Adam BL, Cazares LH. et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 2001;61:6029-33

168. Wang TY, Kawaguchi TP. Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer. Ann Clin Lab Sci. 1986;16:461-6

169. Beckett ML, Cazares LH, Vlahou A. et al. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin Cancer Res. 1999;5:4034-40

170. Murphy GP, Kenny GM, Ragde H. et al. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology. 1998;51:89-97

171. Reiter RE, Gu Z, Watabe T. et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA. 1998;95:1735-40

172. Gu Z, Thomas G, Yamashiro J. et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000;19:1288-96

173. Han KR, Seligson DB, Liu X. et al. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol. 2004;171:1117-21

174. Hara N, Kasahara T, Kawasaki T. et al. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res. 2002;8:1794-9

175. Ross S, Spencer SD, Holcomb I. et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 2002;62:2546-53

176. Saffran DC, Raitano AB, Hubert RS. et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA. 2001;98:2658-63

177. Dannull J, Diener PA, Prikler L. et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res. 2000;60:5522-8

178. Getzenberg RH, Pienta KJ, Huang EY. et al. Identification of nuclear matrix proteins in the cancer and normal rat prostate.Cancer Res. 1991;51:6514-20

179. Uetsuki H, Tsunemori H, Taoka R. et al. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol. 2005;174:514-8

180. Dhir R, Vietmeier B, Arlotti J. et al. Early identification of individuals with prostate cancer in negative biopsies. J Urol.2004;171:1419-23

181. Hansel DE, DeMarzo AM, Platz EA. et al. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. J Urol. 2007;177:1736-40

182. Paul B, Dhir R, Landsittel D. et al. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res. 2005;65:4097-100

183. Epstein JI, Pizov G, Steinberg GD. et al. Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathological stage at radical prostatectomy. J Urol. 1992;148:87-91

184. Partin AW, Steinberg GD, Pitcock RV. et al. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer. 1992;70:161-8

185. Babiarz J, Peters JM, Miles B. et al. Crissman, JD. Comparison of DNA content in primary and lymph node metastases in prostate adenocarcinoma. Anal Quant Cytol Histol. 1993;15:158-64

186. Veltri RW, Partin AW, Epstein JE. et al. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem (Suppl). 1994;19:249-58

187. Carmichael MJ, Veltri RW, Partin AW. et al. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol. 1995;153:1015-19

188. Badalament RA, Miller MC, Peller PA. et al. RW. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol. 1996;156:1375-80

189. Bubendorf L, Tapoa C, Gasser TC. et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol. 1998;29:949-54

190. Su SL, Boynton AL, Holmes EH. et al. Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction. Semin Surg Oncol. 2000;18:17-28

191. Scherr DS, Vaughan EDJ, Wei J. et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol. 1999;162:12-6

192. Feneley MR, Partin AW. Indicators of pathololgic stage of prostate cancer and their use in clinical practice. Urol Clin North Am. 2001;28:443-58

193. Kwiatkowski MK, Recker F, Piironen T. et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic “gray zone” of total PSA 4 to 10 ng/ml. Urology. 1998;52:360-5

194. Becker C, Noldus J, Diamandis E. et al. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci. 2001;38:357-99

195. Haese A, Becker C, Noldus J. et al. Human glandular kallikrein 2. A potential serum marker for predicting the organ-confined versus non-organ-confined growth of prostate cancer. J Urol. 2000;163:1491-7

196. Chapoval AI, Ni J, Lau JS. et al. B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2:269-74

197. Suh WK, Gajewska BU, Okadal H. et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4:899-906

198. Zang X, Allison JP. The B7 family and cancer therapy: Costimulation and coinhibition. Clin Cancer Res. 2007;13:5271-9

199. Luol L, Chapoval AI, Flies DB. et al. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol. 2004;173:5445-50

200. Sun M, Richards S, Prasad DV. et al. Characterization of mouse and human B7-H3 genes. J Immunol. 2002;168:6294-7

201. Petroff MG, Kharatyan E, Torry DS. et al. The immunomodulatory proteins B7-DC, B7-H2, and B7-H3 are differentially expressed across gestation in the human placenta. Am J Pathol. 2005;167:465-73

202. Hofmeyer KA, Ray A, Zang X. The contrasting role of B7-H3. Proc Natl Acad Sci USA. 2008;105:10277-8

203. Roth TJ, Sheinin Y, Lohse CM. et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007;67:7893-900

204. Zang X, Thompson RH, Al-Ahmadie HA. et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007;104:19458-63

205. Chavin G, Sheinin Y, Crispen PL. et al. RJ. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res. 2009;15:2174-80

206. Tsai G, Lane HY, Yang P. et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004;55:452-6

207. Sreekumar A, Poisson LM, Rajendiran TM. et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:799-800

208. Couzin J. Biomarkers. Metabolite in urine may point to high-risk prostate cancer. Science. 2009;323:865

209. Razani B, Schlegel A, Lisanti MP. Caveolin proteins in signaling, oncogenic transformation and muscular dystrophy. Cell Sci. 2000;113:2103-9

210. Okamoto T, Schlegel A, Scherer PE. et al. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem. 1998;273:5419-22

211. Tirado OM, Maccarthy CM, Fatima N. et al. Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer. 2010;126(2):426-36

212. Liedtke C, Kersting C, Burger H. et al. Caveolin-1 expression in benign and malignant lesions of the breast. World J Surg Oncol. 2007;5:110

213. Shatz M, Liscovitch M. Caveolin-1: a tumor-promoting role in human cancer. Int J Radiat Biol. 2008;84:177-89

214. Yang G, Addai J, Wheeler TM. et al. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol. 2007;38:1688-95

215. Barresi V, Cerasoli S, Tuccari G. Correlative evidence that tumor cell-derived caveolin-1 mediates angiogenesis in meningiomas. Neuropathology. 2008;28:472-8

216. Tahir SA, Yang G, Goltsov AA. et al. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer.Cancer Res. 2008;68:731-9

217. Tahir SA, Yang G, Ebara S. et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 2001;61:3882-85

218. Yang G, Truong LD, Timme TL. et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998;4:1873-80

219. Yang G, Troung LD, Wheeler TM. et al. Caveolin-1 expression in clinically confined human cancer: a novel prognostic marker. Cancer Res. 1999;59:5719-23

220. Thompson TC, Tahir SA, Li L. et al. The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic Dis. 2010;13:6-11

221. Di Vizio D, Morello M, Sotgia F. et al. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle. 2009;8:2420-24

222. Tanase CP. Caveolin-1: a marker for pancreatic cancer diagnosis. Expert Rev Mol Diagn. 2008;8:395-404

223. Lin KI, Chattopadhyay N, Bai M. et al. Elevated extracellular calcium can prevent apoptosis via the calcium-sensing receptor. Biochem Biophys Res Commun. 1998;249:325-31

224. Vanaja DK, Grossmann ME, Cheville JC. et al. PDLIM4, an actin binding protein, suppresses prostate cancer cell growth.Cancer Invest. 2009;27:264-72

225. Lallet-Daher H, Roudbaraki M, Bavencoffe A. et al. Intermediate-conductance Ca2+=activated K+ channels (IKcal) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene. 2009;28:1792-806

226. Liao J, Schneider A, Datta NS. et al. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis.Cancer Res. 2006;77:9065-73

227. Schwartz GG. Is serum calcium a biomarker of fatal prostate cancer?. Future Oncol. 2009;5:577-80

228. Vanaja DK, Ballman KV, Morlan BW. et al. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res. 2006;12:1128-36

229. Vanaja DK, Grossmann ME, Cheville JC. et al. PDLIM4, an actin binding protein, suppresses prostate cancer cell growth.Cancer Invest. 2009;27:264-72

230. Bussemakers MJ, van Bokhoven A, Verhaegh GW. et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975-9

231. de Kok JB, Verhaegh GW, Roelofs RW. et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors.Cancer Res. 2002;62:2695-98

232. Kirby RS, Fitzpatrick JM, Irani J. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU Int. 2009Feb;103:441-5

233. Haese A, de la Taille A, van Poppel H. et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54:1081-88

234. Marks LS, Fradet Y, Deras IL. et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.Urology. 2007;69:532-5

235. Chun FK, de la Taille A, van Poppel H, et al.Prostate cancer gene 3 (PCA3). development and internal validation of a novel biopsy nomogram. Eur Urol. 2009;56:659-68

236. Nakanishi H, Groskopf J, Fritsche HA. et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008;179:1804-9

237. Whitman EJ, Groskopf J, Ali A. et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol. 2008;180:1975-8

238. Wang R, Chinnaiyan AM, Dunn RL. et al. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer. 2009;115:3879-86

239. Phé V, Rouprêt M, Salomon L. et al. What's new in 2008 in the field of basic and clinical research in prostate cancer?.Prog Urol. 2009;19:S29-42

240. Fradet Y, Saad F, Aprikian A. et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology.2004;64:311-5

241. Hessels D, Klein Gunnewiek JM, van Oort I. et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8-15

242. Groskopf J, Aubin SM, Deras IL. et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52:1089-95

243. Deras IL, Aubin SM, Blasé A. et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol.2008;179:1587-92

244. Ankerst DP, Groskopf J, Day JR. et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol. 2008;180:1303-8

245. Marks LS, Bostwick DG. Prostate cancer specificity of PCA3 gene testing: examples from clinical practice. Rev Urol.2008;10:175-81

246. Shappell SB, Fulmer J, Arguello D. et al. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology. 2009;73:363-8

247. Ouyang B, Bracken B, Burke B. et al. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol. 2009;181:2508-13

248. Clarke RA, Zhao Z, Guo AY. et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One. 2009;4:e4995

249. Wilson S, Greer B, Hooper J. et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J. 2005;388:967-72

250. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497-511

251. Tomlins SA, Rhodes DR, Perner S. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-8

252. Mwamukonda K, Chen Y, Ravindranath L. et al. Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status. Prostate Cancer Prostatic Dis. 2010;13:47-5

253. Cai C, Wang H, Xu Y. et al. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009;69:6027-32

254. Sardana G, Dowell B, Diamandis EP. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem.2008;54:1951-60

255. Gerdes J, Schwab U, Lemke H. et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20

256. Mosquera JM, Mehra R, Regan MM. et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15:4706-11

257. Yoshimoto M, Joshua AM, Cunha IW. et al. Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol. 2008;21:1451-60

258. Fradet Y. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Curr Opin Urol.2009;19:243-6

259. Keller S, Sanderson MP, Stoeck A. et al. Exosomes: from biogenesis and secretion to biological function. Immunol Lett.2006;107:102-8

260. Valadi H, Ekström K, Bossios A. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654-9

261. Nilsson J, Skog J, Nordstrand A. et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer. 2009;100:1603-7

262. Mitchell PJ, Welton J, Staffurth J, Court J. et al. Can urinary exosomes act as treatment response markers in prostate cancer?. J Transl Med. 2009Jan12;7:4

263. Jansen FH, Krijgsveld J, van Rijswijk A. et al. Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Mol Cell Proteomics. 2009;8:1192-205

264. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-22

265. Gerdes J, Lemke H, Baisch H. et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-5

266. Khatami A, Hugosson J, Wang W. et al. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.Scand J Urol Nephrol. 2009;43:12-8

267. Berney DM, Gopalan A, Kudahetti S. et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer. 2009;100:888-93

268. Khor LY, Bae K, Paulus R. et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol. 2009;27:3177-84

269. Jhavar S, Bartlett J, Kovacs G. et al. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis. 2009;12:143-7

270. Wright LM, Yong S, Picken MM. et al. Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clin Exp Pathol. 2009;2:34-47

271. Wei S, Dunn TA, Isaacs WB. et al. GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus.Prostate. 2008;68:1387-95

272. Laxman B, Morris DS, Yu J. et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008;68:645-9

273. Kristiansen G, Fritzsche FR, Wassermann K. et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer. 2008;99:939-48

274. Chen H, Pong RC, Wang Z. et al. Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics. 2002;79:573-81

275. Chen H, Toyooka S, Gazdar AF. et al. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem. 2003;278:3121-30

276. Wang Z, Tseng CP, Pong RC. et al. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem.2002;277:12622-31

277. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem. 2005;280:22437-44

278. Chen H, Toyooka S, Gazdar AF. et al. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem. 2003;278:3121-30

279. Duggan D, Zheng SL, Knowlton M. et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst. 2007;99:1836-44

Наименование	Объем	Производство	Метод	Кат.Номер
ИФА набор Human Antigen KI-67 (Ki-67)	96	Cusabio	ELISA	CSB-E16294h
ИФА набор Human Apolipoprotein A2,apo-A2	96	Cusabio	ELISA	CSB-E13504h
ИФА набор Human Catenin beta-1 (CTNNB1/CTNNB/OK/SW-cl.35/PRO2286)	96	Cusabio	ELISA	CSB-E08963h
ИФА набор Human Caveolin-1,Cav-1	96	Cusabio	ELISA	CSB-E09682h
ИФА набор Human Chromogranin,CgA	96	Cusabio	ELISA	CSB-E09153h
ИФА набор Human Disabled homolog 2-interacting protein(DAB2IP) ELISA kit	96	Cusabio	ELISA	CSB-EL006481HU
ИФА набор Human E-Cadherin,E-Cad	96	Cusabio	ELISA	CSB-E04519h
ИФА набор Human epidermal growth factor receptor 2 (sp185/HER2)	96	Cusabio	ELISA	CSB-E11161h
ИФА набор Human epidermal growth factor receptor,EGFR	96	Cusabio	ELISA	CSB-E12124h
ИФА набор Human Free Prostate Specific Antigen,fPSA	96	Cusabio	ELISA	CSB-E04769h
ИФА набор Human Free Testosterone,F-TESTO	96	Cusabio	ELISA	CSB-E05096h
ИФА набор Human Glutamate carboxypeptidase 2(FOLH1)	96	Cusabio	ELISA	CSB-EL008782HU
ИФА набор Human High Sensitive Interleukin 6(IL-6) ELISA Kit	96	Cusabio	ELISA	CSB-E16546h
ИФА набор Human Kallikrein 2(hK 2)	96	Cusabio	ELISA	CSB-E13094h
ИФА набор Human pro-gastrin-releasing peptide, ProGRP	96	Cusabio	ELISA	CSB-E09127h
ИФА набор Human prostate specific antigen,PSA	96	Cusabio	ELISA	CSB-E04768h
ИФА набор Human Prostate stem cell antigen(PSCA)	96	Cusabio	ELISA	CSB-EL018840HU
ИФА набор Human sex hormone-binding globulin,SHBG	96	Cusabio	ELISA	CSB-E08232h
ИФА набор Human Soluble Endoglin,sENG/sCD105	96	Cusabio	ELISA	CSB-E10030h
ИФА набор Human thrombospondin 1,TSP-1	96	Cusabio	ELISA	CSB-E08763h
ИФА набор Human total prostate s pecific antigen,tPSA ELISA Kit	96	Cusabio	ELISA	CSB-E09627h
ИФА набор Human Transforming Growth factor β1,TGF-β1 ELISA kit	96	Cusabio	ELISA	CSB-EL023446HU
ИФА набор Human Ultra Sensitive Prostate Specific Antigen,PSA U S ELISA Kit	96	Cusabio	ELISA	CSB-E08989h
ИФА набор для определения лептина человека (Leptin, LEP)	96	Cusabio	ELISA	CSB-E04649h
ИФА набор Интерлейкин 6 (IL-6, Интерлейкин 6)	96	Cusabio	ELISA	CSB-E04638h
ИФА набор матриксная металлопротеиназа-9, (MMP-9) человека	96	Cusabio	ELISA	CSB-E08006h
ИФА набор Нейрон специфическая енолаза человека (Neuron-specific enolase, NSE)	96	Cusabio	ELISA	CSB-E07961h
ИФА набор Пептид, связанный с геном кальцитонина человека (calcitonin gene related peptide, CGRP)	96	Cusabio	ELISA	CSB-E08210h
ИФА набор рецептор урокиназы, активатора плазминогена (uPAR) человека	96	Cusabio	ELISA	CSB-E04752h
ИФА набор тканевой ингибитор металлопротеиназы-1, (TIMP-1) человека	96	Cusabio	ELISA	CSB-E08003h
ИФА набор тканевой ингибитор металлопротеиназы-2, (TIMP-2) человека	96	Cusabio	ELISA	CSB-E04733h
ИФА набор Трансформирующий фактор роста бета 2 человека (transforming growth factors β2,TGFβ2)	96	Cusabio	ELISA	CSB-E09783h
ИФА набор Трансформирующий фактор роста бета 3 человека (Transforming Growth factor β3, TGF-β3)	96	Cusabio	ELISA	CSB-E13738h
ИФА набор фактор некроза опухолей альфа, (TNF-α) человека	96	Cusabio	ELISA	CSB-E04724h
ИФА набор фактор роста гепатоцитов, (HGF) человека	96	Cusabio	ELISA	CSB-E04573h
ИФА набор Фактор, ингибирующий миграцию макрофагов человека (Macrophage Migration Inhibitory Factor, MIF)	96	Cusabio	ELISA	CSB-E08330h
Хромогранин А	96 wells	Dako	ELISA	K002511